Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Other financing activities (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Other financing activities readings, the most recent being $1.5 million for Q3 2025.

  • Quarterly Other financing activities rose 159.74% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Sep 2025, up 324.81% year-over-year, with the annual reading at $7.3 million for FY2024, 205.01% up from the prior year.
  • Other financing activities hit $1.5 million in Q3 2025 for Greenwich LifeSciences, roughly flat from $1.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $5.5 million in Q4 2024 and bottomed at $165051.0 in Q1 2021.
  • Average Other financing activities over 5 years is $877289.7, with a median of $594522.0 recorded in 2022.
  • The largest annual shift saw Other financing activities decreased 21.73% in 2023 before it soared 820.03% in 2024.
  • Greenwich LifeSciences' Other financing activities stood at $165429.0 in 2021, then soared by 259.38% to $594522.0 in 2022, then changed by 0.0% to $594522.0 in 2023, then soared by 820.03% to $5.5 million in 2024, then tumbled by 71.77% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Other financing activities are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.5 million (Q1 2025).